{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:28:56Z","timestamp":1782552536457,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Opioid-induced constipation (OIC) is one of the most prevalent adverse events associated with cancer patients who receive opioid analgesics for moderate to severe pain. Acupuncture may be an effective treatment for OIC. We designed this trial to assess the efficacy and safety of electroacupuncture for OIC in cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a multicenter, sham-controlled, parallel-group, subject- and assessor-blinded randomized trial. A total of 100 cancer patients with OIC will be randomly assigned to either the electroacupuncture group or the sham electroacupuncture group at a ratio of 1:1. Patients in each group will receive a total of 24-session treatment over 8 weeks, three sessions a week and 30 min each session. Thereafter, patients will be followed up for another 8 weeks. The primary outcome will be the proportion of responders, defined as a patient who has \u22653 spontaneous bowel movements (SBMs)\/wk and \u2265 increase of 1 SBM from baseline simultaneously for at least 6 out of 8 weeks of the treatment period. The secondary outcomes will include the mean weekly SBMs and complete spontaneous bowel movements, the mean Bristol Stool Form Scale score for stool consistency, the mean score for straining of SBM, the total and subscale scores of Patient Assessment of Constipation-Symptom questionnaires, and the total and subscale scores of Patient Assessment of Constipation-Quality of Life questionnaire. Patients' global assessment of treatment effectiveness, patients' expectation toward the effectiveness of acupuncture and safety of acupuncture will also be assessed. All efficacy analyses will be performed in the intention-to-treat population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>To improve the adherence to intervention protocols, the majority of the participants will be recruited from an inpatient setting. The results will help to determine the clinical effects and safety of electroacupuncture for the treatment of OIC among patients with cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>www.ClinicalTrials.gov<\/jats:ext-link>, identifier: NCT03797586, registered on 4 January 2019, <jats:ext-link>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03797586<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.818258","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T08:03:05Z","timestamp":1649836985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Electroacupuncture on Opioid-Induced Constipation in Patients With Cancer: Study Protocol for a Multicenter Randomized Controlled Trial"],"prefix":"10.3389","volume":"9","author":[{"given":"Weiming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1470-2045(09)70350-X","article-title":"Intravenous morphine for management of cancer pain","volume":"11","author":"Mercadante","year":"2010","journal-title":"Lancet Oncol."},{"key":"B3","volume-title":"Cancer Pain Relief With A Guide To Opioid Availability. 2nd ed.","year":"1996"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1016\/S0959-8049(01)80031-9","article-title":"The pharmacological management of cancer pain","volume":"37","author":"Cherny","year":"2001","journal-title":"Eur J Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/MEG.0b013e32834d1938","article-title":"Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis","volume":"23","author":"Luo","year":"2011","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/phar.1223","article-title":"Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid- related adverse events and their impact on clinical and economic outcomes","volume":"33","author":"Kessler","year":"2013","journal-title":"Pharmacotherapy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1345\/aph.1H386","article-title":"Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay","volume":"41","author":"Oderda","year":"2007","journal-title":"Ann Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1756283X15589526","article-title":"Evolving paradigms in the treatment of opioid-induced bowel dysfunction","volume":"8","author":"Poulsen","year":"2015","journal-title":"Therap Adv Gastroenterol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain."},{"key":"B12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1191\/026921698674125048","article-title":"The relationship between opioid use and laxative use in terminally ill cancer patients","volume":"12","author":"Sykes","year":"1998","journal-title":"Palliat Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-014-0254-6","article-title":"Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone\/naloxone","volume":"35","author":"Morlion","year":"2015","journal-title":"Clin Drug Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.2147\/DDDT.S92998","article-title":"Efficacy and tolerability of oral oxycodone and oxycodone\/ naloxone combination in opioid-na\u00efve cancer patients: a propensity analysis","volume":"9","author":"Lazzari","year":"2015","journal-title":"Drug Des Devel Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/ajg.2011.30","article-title":"Opioid-induced constipation: challenges and therapeutic opportunities","volume":"106","author":"Camilleri","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/papr.12535","article-title":"Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"17","author":"Rauck","year":"2017","journal-title":"Pain Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0032-1301753","article-title":"Evaluation of constipation","volume":"25","author":"Alame","year":"2012","journal-title":"Clin Colon Rectal Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.sjpain.2015.12.005","article-title":"Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction\u2014recommendations of the Nordic Working Group","volume":"11","author":"Drewes","year":"2016","journal-title":"Scand J Pain."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/pm\/pnw255","article-title":"Opioid-induced constipation and bowel dysfunction: a clinical guideline","volume":"18","author":"M\u00fcller-Lissner","year":"2016","journal-title":"Pain Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S2468-1253(18)30008-6","article-title":"Pathophysiology, diagnosis, and management of opioid-induced constipation","volume":"3","author":"Farmer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B21","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","volume":"7","author":"Slatkin","year":"2009","journal-title":"J Support Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/acupmed-2016-011127","article-title":"Comparison of electroacupuncture and medical treatment for functional constipation: a systematic review and meta-analysis","volume":"35","author":"Zhou","year":"2017","journal-title":"Acupunct Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1142\/S0192415X13500493","article-title":"Efficacy of acupuncture for chronic constipation: a systematic review","volume":"41","author":"Zhang","year":"2013","journal-title":"Am J Chin Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7326\/M15-3118","article-title":"Acupuncture for chronic severe functional constipation: a randomized trial","volume":"165","author":"Liu","year":"2016","journal-title":"Ann Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.14309\/ajg.0000000000001050","article-title":"Electroacupuncture vs. prucalopride for severe chronic constipation: a multicenter, randomized, controlled, noninferiority trial","volume":"116","author":"Liu","year":"2021","journal-title":"Am J Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1525-1403.2010.00295.x","article-title":"Mechanism of acupuncture on neuromodulation in the gut\u2013a review","volume":"14","author":"Takahashi","year":"2011","journal-title":"Neuromodulation."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ."},{"key":"B28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1756-5391.2010.01086.x","article-title":"Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement","volume":"3","author":"MacPherson","year":"2010","journal-title":"J Evid Based Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/1472-6882-14-260","article-title":"Effect of electroacupuncture versus prucalopride for severe chronic constipation: protocol of a multi-centre, non-inferiority, randomised controlled trial","volume":"14","author":"Liu","year":"2014","journal-title":"BMC Complement Altern Med."},{"key":"B31","volume-title":"GB\/ T12346-2006, Nomenclature and Location of Acupuncture Points.","year":"2006"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1089\/acm.2010.0652","article-title":"Characterization of de qi with electroacupuncture at acupoints with different properties","volume":"17","author":"Zhou","year":"2011","journal-title":"J Altern Complement Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","article-title":"A placebo- controlled trial of prucalopride for severe chronic constipation","volume":"358","author":"Camilleri","year":"2008","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/apt.14349","article-title":"The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference","volume":"46","author":"Yiannakou","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3870\/hlxzz.2012.07.073","article-title":"Validation of the Chinese version of PAC-SYM questionnaire","volume":"27","author":"Song","year":"2012","journal-title":"J Nurs Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the patient assessment of constipation quality of life questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand J Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.11569\/wcjd.v19.i2.209","article-title":"Evaluation of the Chinese version of the patient assessment of constipation quality of life scale","volume":"19","author":"Jin","year":"2011","journal-title":"World Chinese J Digestol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0001-6918(99)00050-5","article-title":"Optimal number of response categories in rating scales: reliability, validity, discriminating power, and respondent preferences","volume":"104","author":"Preston","year":"2000","journal-title":"Acta Psychol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: a systematic review and meta-analysis","volume":"16","author":"Nee","year":"2018","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.818258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T08:03:11Z","timestamp":1649836991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.818258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":41,"alternative-id":["10.3389\/fmed.2022.818258"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.818258","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"article-number":"818258"}}